Ankylosing Spondylitis Trial, Recruiting NCT06642207 Sponsor: Sohag University Condition: Ankylosing Spondylitis
Back to Ankylosing Spondylitis

Ankylosing Spondylitis Trial, Recruiting

NCT06642207
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a specific type of inflammatory spinal condition called Axial Spondyloarthritis, based on recognised international classification standards.
  • You have had this condition for more than 6 months.
  • You have already tried standard treatments that did not work well enough, and you are currently taking a type of biological medication (either an IL-17 blocker or an anti-TNF-alpha drug).
  • You are older than 16 years of age.
  • You are able to understand and answer questions during the study.
  • You are willing and able to sign a written consent form agreeing to take part.

Who may not be able to join:

  • You have another rheumatic or connective tissue disease (such as lupus or rheumatoid arthritis).
  • You are under 16 years old or over 60 years old.
  • You are unable or unwilling to cooperate with the study requirements.
  • You are unwilling or unable to sign a written consent form.
  • You have any other condition that affects how your platelets (blood clotting cells) function or your platelet count (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 01032330664

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 October 2024
Est. completion
1 July 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Effect of IL17 Inhibitor in comparison with Anti-TNFα on Platelet count; Platelet count association with disease activity in patients with Ankylosing Spondylitis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov